Thiabendazole/Neomycin/Dexamethason
49 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 49 |
| Reports involving death | 0 |
| Case-fatality rate (reported events) | 0.0% |
| Distinct species in reports | 4 |
| Distinct breeds in reports | 20 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 1 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Thiabendazole/Neomycin/Dexamethason Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 49 adverse event reports referencing Thiabendazole/Neomycin/Dexamethason, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Thiabendazole/Neomycin/Dexamethason. Reported administration routes include Unknown, Auricular (Otic), Ophthalmic, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Thiabendazole/Neomycin/Dexamethason reports are Dog (20 reports), Unknown (14 reports), Human (8 reports), with Dog accounting for the largest share. Within those species, Unknown (22), Domestic Shorthair (6), Terrier - West Highland White (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Thiabendazole/Neomycin/Dexamethason are Uncoded sign (14), Dropper, Abnormal (5), Eye irritation (5), Caps, Abnormal (4). Of the 35 reports with a coded outcome, Outcome Unknown is the leading category at 71.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Thiabendazole/Neomycin/Dexamethason.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.